Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Kahn

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Learning Health Systems|July 19, 2021
Seven practices for pursuing equity through learning health systems: Notes from the fieldAllison Parsons, Ndidi I Unaka, Constance Stewart, et al.
Health & Social Care in the Community|February 9, 2021
Cultivating social relationships and disrupting social isolation in low-income, high-disparity neighbourhoods in Ohio, USAAllison A Parsons, Dawna Leggett, Daniela Vollmer, et al.
Journal of the American Medical Directors Association|December 8, 2020
Online Education and Cognitive Behavior Therapy Improve Dementia Caregivers' Mental Health: A Randomized TrialJane Fossey, Georgina Charlesworth, Jo-Ann Fowler, et al.
JPGN Reports|June 16, 2022
Health-Related Social Needs Facing Youth with NonAlcoholic Fatty Liver DiseaseSarah Orkin, Toshifumi Yodoshi, Qin Sun, et al.
The American Journal of Cardiology|February 17, 2018
Corrigendum to 'Effects of RG7652, a Monoclonal Antibody Against PCSK9, on Low-Density Lipoprotein Cholesterol (LDL-C), LDL-C Subfractions, and Inflammatory Biomarkers in Patients at High Risk of or with Established Coronary Heart Disease (From the Phase 2 EQUATOR Study)' The American Journal of Cardiology 119 (2017) 1576-1583Amos Baruch, Sofia Mosesova, John D Davis, et al.
The American Journal of Cardiology|March 28, 2017
Effects of RG7652, a Monoclonal Antibody Against PCSK9, on LDL-C, LDL-C Subfractions, and Inflammatory Biomarkers in Patients at High Risk of or With Established Coronary Heart Disease (from the Phase 2 EQUATOR Study)Amos Baruch, Sofia Mosesova, John D Davis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 8, 2016
Phase I Study of the Anti-CD22 Antibody-Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin LymphomaRanjana H Advani, Daniel Lebovic, Andy Chen, et al.
Journal of Pediatric Gastroenterology and Nutrition|October 26, 2019
Community Socioeconomic Deprivation and Nonalcoholic Fatty Liver Disease SeveritySarah Orkin, Cole Brokamp, Toshifumi Yodoshi, et al.
The Lancet. Oncology|May 1, 2015
Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 studyMaria Corinna A Palanca-Wessels, Myron Czuczman, Gilles Salles, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 22, 2019
Phase Ia Study of Anti-NaPi2b Antibody-Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Patients with Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian CancerDavid E Gerber, Jeffrey R Infante, Michael S Gordon, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Learning Health Systems|July 19, 2021
Seven practices for pursuing equity through learning health systems: Notes from the fieldAllison Parsons, Ndidi I Unaka, Constance Stewart, et al.
Health & Social Care in the Community|February 9, 2021
Cultivating social relationships and disrupting social isolation in low-income, high-disparity neighbourhoods in Ohio, USAAllison A Parsons, Dawna Leggett, Daniela Vollmer, et al.
Journal of the American Medical Directors Association|December 8, 2020
Online Education and Cognitive Behavior Therapy Improve Dementia Caregivers' Mental Health: A Randomized TrialJane Fossey, Georgina Charlesworth, Jo-Ann Fowler, et al.
JPGN Reports|June 16, 2022
Health-Related Social Needs Facing Youth with NonAlcoholic Fatty Liver DiseaseSarah Orkin, Toshifumi Yodoshi, Qin Sun, et al.
The American Journal of Cardiology|February 17, 2018
Corrigendum to 'Effects of RG7652, a Monoclonal Antibody Against PCSK9, on Low-Density Lipoprotein Cholesterol (LDL-C), LDL-C Subfractions, and Inflammatory Biomarkers in Patients at High Risk of or with Established Coronary Heart Disease (From the Phase 2 EQUATOR Study)' The American Journal of Cardiology 119 (2017) 1576-1583Amos Baruch, Sofia Mosesova, John D Davis, et al.
The American Journal of Cardiology|March 28, 2017
Effects of RG7652, a Monoclonal Antibody Against PCSK9, on LDL-C, LDL-C Subfractions, and Inflammatory Biomarkers in Patients at High Risk of or With Established Coronary Heart Disease (from the Phase 2 EQUATOR Study)Amos Baruch, Sofia Mosesova, John D Davis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 8, 2016
Phase I Study of the Anti-CD22 Antibody-Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin LymphomaRanjana H Advani, Daniel Lebovic, Andy Chen, et al.
Journal of Pediatric Gastroenterology and Nutrition|October 26, 2019
Community Socioeconomic Deprivation and Nonalcoholic Fatty Liver Disease SeveritySarah Orkin, Cole Brokamp, Toshifumi Yodoshi, et al.
The Lancet. Oncology|May 1, 2015
Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 studyMaria Corinna A Palanca-Wessels, Myron Czuczman, Gilles Salles, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 22, 2019
Phase Ia Study of Anti-NaPi2b Antibody-Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Patients with Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian CancerDavid E Gerber, Jeffrey R Infante, Michael S Gordon, et al.
Pageof 3